Edition:
United States

Biomerieux SA (BIOX.PA)

BIOX.PA on Paris Stock Exchange

150.00EUR
11:35am EST
Change (% chg)

€-0.40 (-0.27%)
Prev Close
€150.40
Open
€150.25
Day's High
€151.30
Day's Low
€149.95
Volume
18,916
Avg. Vol
29,232
52-wk High
€153.25
52-wk Low
€97.17

Latest Key Developments (Source: Significant Developments)

FDA clears test to help manage antibiotic treatment for lower respiratory tract infections and sepsis
5:41pm EST 

Biomerieux Sa : U.S. FDA clears test to help manage antibiotic treatment for lower respiratory tract infections and sepsis . U.S. FDA - cleared expanded use of Vidas Brahms percent assay to help manage antibiotic treatment for lower respiratory tract infections and sepsis .U.S. FDA - Vidas Brahms test is manufactured by Biomérieux Inc.  Full Article

Biomerieux 2016 sales up at 2,103 million euros
Thursday, 19 Jan 2017 01:01am EST 

Biomerieux SA : Remarkable growth in sales in 2016, up 9.6 pct like-for-like, lifted by all regions and all strategic lines . Consolidated sales amounted to 2,103 million euros ($2.24 billion) in 2016, versus 1,965 million euros in 2015 .For FY, expects contributive operating income before non-recurring items to be slightly above its previous target, moving closer to 300 million euros.  Full Article

Biomerieux and Banyan Biomarkers partner to develop, validate and market blood-based biomarkers for traumatic brain injury
Thursday, 19 Jan 2017 01:00am EST 

Biomerieux SA : Biomerieux and Banyan Biomarkers partner to develop, validate and market blood-based biomarkers for traumatic brain injury . Under terms of agreement, Biomerieux takes equity participation of about $7 million in Banyan Biomarkers . Obtains rights to commercialize Banyan's proprietary tests worldwide for use in in vitro diagnostics, with preferred rights for its Vidas Immunoassays range .In addition, two companies will continue to explore co-development opportunities in area of TBI and critical care.  Full Article

Biomerieux introduces Evisight Compact
Thursday, 6 Oct 2016 01:00am EDT 

Biomerieux SA :Biomerieux introduces Evisight Compact, a new automated diagnostic solution for microbial detection in pharmaceutical production.  Full Article

Biomerieux 2016 guidance revised to top of range
Wednesday, 31 Aug 2016 01:00am EDT 

Biomerieux SA : H1 net income of consolidated companies 86 million euros ($95.9 million) versus 59 million euros a year ago . 2016 financial targets revised . 2016 organic sales growth could end year at or above higher end of previously targeted 6.0 pct to 8.0 pct range . FY contributive operating income before non-recurring items expected to come in at around the top of the initially targeted 265 million euros to 290 million euros range . Consolidated net debt amounted to 265 million euros at June 30, 2016 versus 219 million euros at December 31, 2015 .H1 operating income 146 million euros versus 103 million euros year ago.  Full Article

Biomerieux H1 sales up 10.9 pct, at constant exchange rates and scope of consolidation
Monday, 18 Jul 2016 01:00am EDT 

Biomerieux SA : Strong growth in sales, up 10.9 pct, at constant exchange rates and scope of consolidation in first half of 2016 .H1 sales reached 1,001 million euros ($1.11 billion).  Full Article

Biomerieux reports Q2 growth in sales of 10.9 pct
Monday, 18 Jul 2016 01:00am EDT 

Biomerieux SA : Q2 strong growth in sales, up 10.9 pct, at constant exchange rates and scope of consolidation in first half of 2016 .Q2 sales reached 1,001 million euros ($1.11 billion).  Full Article

Biomerieux and Lyon Civil Hospitals expand their partnership
Wednesday, 1 Jun 2016 01:36am EDT 

Biomerieux SA :Said on Tuesday Biomerieux and the Lyon Civil Hospitals strengthen their collaboration and expand their partnership to include Claude Bernard University Lyon 1.  Full Article

Biomerieux acquires Hyglos
Wednesday, 1 Jun 2016 01:00am EDT 

Biomerieux SA : Biomérieux acquires Hyglos and expands its offering to the detection of endotoxins in pharmaceutical products . Total consideration paid by Biomerieux to acquire 100 pct of Hyglos shares will amount to 24 million euros ($26.69 million) . Total consideration paid by Biomerieux to acquire 100 pct of Hyglos phased over next 3 years . Transaction was closed on May 31, 2016 .Hyglos will be consolidated in group`s financial statements from June 1st, 2016.  Full Article

Biomerieux : Filmarray Torch is FDA cleared
Friday, 8 Apr 2016 01:00am EDT 

Biomerieux SA:Filmarray Torch is now FDA cleared with all 4 existing Filmarray panels and the system gets CE marked.  Full Article

More From Around the Web

BRIEF-Biomerieux and Banyan Biomarkers partner to develop, validate and market blood-based biomarkers for traumatic brain injury

* Biomerieux and Banyan Biomarkers partner to develop, validate and market blood-based biomarkers for traumatic brain injury